

Clinical trials of anticoagulant for post stroke in all type of patients

TrialResults-center www.trialresultscenter.org

1 ADO

Trial	Treatments	Patients	Trials design and methods
rivaroxaban vs aspirin			
NAVIGATE ESUS , 2018 [NCT02313909] n=3609/3604	rivaroxaban (at a daily dose of 15 mg) versus aspirin (at a daily dose of 100 mg)	patients with recent ischemic stroke that was presumed to be from cerebral embolism but without arterial stenosis, lacune, or an identified cardioembolic source	

References

NAVIGATE ESUS, 2018:

Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, Davalos A, Shalalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisum Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med 2018;378:2191-2201 [29766772]

2 anticoagulant

Trial	Treatments	Patients	Trials design and methods
warfarin vs aspirin			
SWAT , 1998 n=NA follow-up: 2 years	warfarin (INR 2.0 to 3.0) versus Enteric-coated aspirin 650 mg 12-hourly	-	Parallel groups open USA
anticoagulant vs no anticoagulant			
Baker , 1964 n=NA follow-up:	unnamed anticoagulant (TQ (2 to 2.5 times control in seconds), started in hospital) versus no treatment	-	Parallel groups open
Bradshaw , 1975 n=NA follow-up:	warfarin or phenindione for 18 mo; TP time 2x control versus no treatment	-	Parallel groups open UK
LHSPS , 1999 n=NA follow-up: 2 years	unfractionated heparin 12.500 IU/d plus usual therapy versus usual therapy	-	Parallel groups open Italy

continued...

Trial	Treatments	Patients	Trials design and methods
VA Study , 1961 n=NA follow-up: 11 months	coumadin or dicumarol, prothrombin activity 20% of normal versus no treatment	-	Parallel groups open USA
Wallace , 1964 n=NA follow-up: 9.75 months	phenindione or warfarin, Quick test 20% to 35% of normal (50% after 10 months) versus no treatment	-	Parallel groups open Australia
anticoagulant vs placebo			
McDevitt , 1959 n=NA follow-up: 34 months	dicumarol or warfarin, Quisk test 2 to 2.5 times control in seconds versus placebo	-	Parallel groups single-blind USA
dicoumarol vs placebo			
Howard , 1963 n=NA follow-up: 1 year	dicumarol, TP 15 to 25% of normal versus placebo	-	Parallel groups single-blind USA
Nat-Coop , 1962 n=NA follow-up: 13 months	heparin 50 mg 4-hourly iv then dicumarol, Quick test 15% to 25% of control versus placebo	-	Parallel groups single-blind USA
phenindione vs placebo			
Enger , 1965 n=NA follow-up: 22.7 months	phenindione thrombotest 10% to 25% of normal, started in hospital versus placebo	-	Parallel groups single-blind Norway
Thygesen , 1964 n=NA follow-up: 29.5 months	phenindione, prothrombin-proconvertin test 10% to 20% versus placebo	-	Parallel groups single-blind Denmark

References

SWAT, 1998:

Stewart B, Shuaib F, Veloso F. Stroke Prevention with Warfarin or Aspirin Trial (SWAT) Stroke 1998;29:304.

Baker, 1964:

Baker RN, Schwartz WS, Rose MD Transient ischemic strokes. A report of a study of anticoagulant therapy. Neurology 1966;16:841-7.

Baker RN, Schwartz WS, Rose MD Transient ischemic strokes. A report of a study of anticoagulant therapy. Neurology 1966;16:841-7.

Baker RN, Schwartz WS, Rose MD Transient ischemic strokes. A report of a study of anticoagulant therapy. Neurology 1966;16:841-7.

Bradshaw, 1975:

Bradshaw P, Brennan S Trial of long-term anticoagulant therapy in the treatment of small stroke associated with a normal carotid angiogram. Journal of Neurology, Neurosurgery and Psychiatry 1975;38:642-7.

Bradshaw P, Brennan S Trial of long-term anticoagulant therapy in the treatment of small stroke associated with a normal carotid angiogram. Journal of Neurology, Neurosurgery and Psychiatry 1975;38:642-7.

Bradshaw P, Brennan S Trial of long-term anticoagulant therapy in the treatment of small stroke associated with a normal carotid angiogram. *Journal of Neurology, Neurosurgery and Psychiatry* 1975;38:642-7.

LHSPS, 1999:

Fortini A, Bonechi G, Carnovali M, Olivo G, Rinaldi G, Gensini GF Multi-centric study on ischemic cerebral re-infarct prevention with low-dose heparin: the informatic system [Sistema informatico dello studio clinico controllato multicentrico sulla prevenzione del reinfarto cerebrale ischemico con eparina a basso dosaggio]. *Rivista di Neurobiologica*

Fortini A, Bonechi G, Carnovali M, Olivo G, Rinaldi G, Gensini GF Multi-centric study on ischemic cerebral re-infarct prevention with low-dose heparin: the informatic system [Sistema informatico dello studio clinico controllato multicentrico sulla prevenzione del reinfarto cerebrale ischemico con eparina a basso dosaggio]. *Rivista di Neurobiologica*

Fortini A, Bonechi G, Carnovali M, Olivo G, Rinaldi G, Gensini GF Multi-centric study on ischemic cerebral re-infarct prevention with low-dose heparin: the informatic system [Sistema informatico dello studio clinico controllato multicentrico sulla prevenzione del reinfarto cerebrale ischemico con eparina a basso dosaggio]. *Rivista di Neurobiologica*

VA Study, 1961:

Baker RN. An evaluation of anticoagulant therapy in the treatment of cerebrovascular disease. Report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section *Neurology* 1961;11:1328.

Wallace, 1964:

WALLACE DC CEREBRAL VASCULAR DISEASE IN RELATION TO LONG-TERM ANTICOAGULANT THERAPY. *J Chronic Dis* 1964;17:527-37 [[14168625](#)]

McDevitt, 1959:

McDEVITT E, GROCH SN, WRIGHT IS A cooperative study of cerebrovascular disease; methodology and a preliminary report on the use of anticoagulants. *Circulation* 1959;20:215-23 [[13671708](#)]

McDowell F, McDevitt E, Wright IS. Anticoagulant therapy: five years experience with the patient with an established cerebrovascular accident.-ms *Archives of Neurology* 1963;8:20914

Howard, 1963:

HOWARD FA, COHEN P, HICKLER RB, LOCKES, NEWCOMB T, TYLER HR Survival following stroke *JAMA* 1963;183:921-5 [[13955115](#)]

Nat-Coop, 1962:

FISHER CM Anticoagulant therapy in cerebral thrombosis and cerebral embolism. A national cooperative study, interim report. *Neurology* 1961;11(4)Pt 2:119-31 [[13699939](#)]

Enger, 1965:

Enger E, Boyesen S Long-term anticoagulant therapy in patients with cerebral infarction: a controlled clinical study. *Acta Medica Scandinavica* 1965;178 Suppl 438:7-61.

Enger E, Boyesen S Long-term anticoagulant therapy in patients with cerebral infarction: a controlled clinical study. *Acta Medica Scandinavica* 1965;178 Suppl 438:7-61.

Enger E, Boyesen S Long-term anticoagulant therapy in patients with cerebral infarction: a controlled clinical study. *Acta Medica Scandinavica* 1965;178 Suppl 438:7-61.

Thygesen, 1964:

THYGESEN P, CHRISTENSEN E, DYRBYE M, EIKEN M, FRANTZEN E, GORMSEN J, LADEMANN A, LENNOX-BUCHTHAL M, RONNOV-JESSEN V, THERKELSEN J CEREBRAL APOPLEXY. A CLINICAL, RADIOLOGICAL, ELECTROENCEPHALOGRAPHIC AND PATHOLOGICAL STUDY WITH SPECIAL REFERENCE TO THE PROGNOSIS OF CEREBRAL INFARCTION AND THE RESULT OF LONG-TERM ANTICOAGULATION THERAPY. *Dan Med Bull* 1964;11:233-57 [[14250709](#)]

3 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.